Single-use technology is the new norm in the pharma manufacturing process due to an array of benefits. The availability of this technology has made new biopharmaceutical companies adopt single-use systems, as it requires less upfront capital investment and enables quick advancement of development efforts towards new products. Having an upper hand, the single-use technology is vouched to be a game changer in the entire manufacturing process.
India has, unfortunately, turned into the diabetes capital of the world with even more patients being added every passing year. This is adding to the growing healthcare burden on the Indian economy and has become a major cause of concern for the Centre as well. The government is aware and seems to be taking steps to combat this by bringing down the cost price of a few, newly launched drugs used for diabetes. Pharma companies, too, are seeing a new growth opportunity by innovating new drugs and therapeutic combinations. As there are already numerous drug options available, is there a need to further add to the pool of newer, innovative drugs? Let’s explore.